Belgo-Dutch biotech argenx (Euronext Brussels: ARGX) yesterday announced an exclusive, global collaboration and license agreement for cusatuzumab (ARGX-110), adding to its lucrative deal in the summer with AbbVie (NYSE: ABBV), with the news sending its share leaping 13% to 10.90 euros by close of trading on Monday.
Cusatuzumab, a highly differentiated anti-CD70 SIMPLE AntibodyÔ, has been licensed to Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ).
Cusatuzumab is currently in development in a Phase I/II combination study with Vidaza (azacitidine) for newly-diagnosed, elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) who are unfit for chemotherapy. Data announced from the Phase I/II study will be presented during a workshop being held in conjunction with the 60th American Society of Hematology Annual Meeting and Exposition.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze